The NORDTREAT project will build on the achievements within recent large-scale European initiatives that includes cross-disciplinary collaborations between academia, hospitals, biomedical companies and patient organisations. The overall aim is to improve Inflammatory bowel disease (IBD) patients' prognosis and quality of life by introducing a novel personalized medicine algorithm that is based on recently generated -omics data. IBD is a disease entity of unknown origin, characterized by a chronic inflammation in the gastrointestinal tract. IBD is increasing, especially among teenagers, and today 0.5-1% of the Nordic population is affected. The disease course varies from an indolent course to an aggressive, treatment refractory disease, with need of repeated hospital admissions, surgery and increased risk of comorbidity including cancer. Thus, IBD have severe consequences for many affected individuals, including life-long medication, hospitalizations, recurring sick-leaves,

Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces lifeexpectance. Many disease mechanisms and risk factors are known in IHD, but we need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified. The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm.

Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance. Many disease mechanisms and risk factors are known in IHD, but we urgently need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified. The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm

Globally, the leading cause of years of life lost is ischemic heart disease (IHD). IHD causes chest pain, myocardial infarcts, reduced physical capacity and reduces life-expectance. Many disease mechanisms and risk factors are known in IHD, but we urgently need approaches to manage complex data that can drive precise sub-classifications and risk stratification rather than continuing present “one-size-fits-all” regimes, which in many cases is an inefficient, costly, potentially harmful over-management. At the same time, patients at high risk may not be identified. The objective is to develop and clinically implement personalized medicine (PM) in IHD to avoid overtreatment as well as undertreatment. This will be achieved by a Nordic interdisciplinary collaboration by merging large cohorts with well-described IHD geno- and phenotype data; clinical data, Nordic national registry data, genetics, socio-economics, trajectories of co-morbidities, medications etc into The Heart IHD Algorithm

The PERAID project proposes to implement personalized medicine (PM) in severe infectious diseases, specifically focusing on the life-threatening necrotizing soft tissue infections (NSTI) as well as the large heterogeneous group of sepsis patients. Personalized medicine is a neglected, albeit much desired, development in the field of acute infectious diseases. The patient population is highly heterogeneous with different pathogens, pathogenic mechanisms, as well as varying predisposing host factors, and importantly, a dysregulated host response to infection is directly linked to severity and outcome of severe infections, i.e. sepsis and NSTI. PERAID builds on the advances and resources created in the EU FP7-project INFECT, including the worlds largest patient cohort on NSTI (Scandinavian patients enrolled by PERAIDs partners from Denmark, Norway and Sweden), biobank, multi-omics data, and pathophysiologic models.

Please see upload Rheumatoid arthritis (RA, life-time risk around 2%) entails a considerable burden for affected individuals (pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced work ability, and treatment costs that currently accounts for almost 10% of the total drug expenditure). Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality. RA demonstrates a striking heterogeneity in terms of clinical presentation, response to treatment, and clinical outcomes. Emerging data suggest that RA is not one disease but comprised by subsets with distinct etiologies, which may explain the difficulties in predicting disease course, treatment response, and long-term outcomes. So far we treat by tradition and try different treatments in a rather random fashion and often too late, despite the increasing number of different, and still expensive, medicines that have become available in rout

Rheumatoid arthritis (RA, life-time risk around 2%) entails a considerable burden for affected individuals (pain, reduced life-span, reduced function, reduced quality of life), for health-care, and for society (reduced work ability, and treatment costs that currently accounts for almost 10% of the total drug expenditure). Delayed or ineffective treatment leads to joint destruction, co-morbidities, and increased mortality. RA demonstrates a striking heterogeneity in terms of clinical presentation, response to treatment, and clinical outcomes. Emerging data suggest that RA is not one disease but comprised by subsets with distinct etiologies, which may explain the difficulties in predicting disease course, treatment response, and long-term outcomes. So far we treat by tradition and try different treatments in a rather random fashion and often too late, despite the increasing number of different, and still expensive, medicines that have become available in routine care. ...

The aim of the project is to demonstrate the value of targeted bacteriophage treatments in reducing the impact of antibiotic resistant E. coli strains, using chicken septicaemia as a model. This project also has the potential for significant One Health impacts, given the similarities between pathogenic E. coli strains that infect animals and humans. It is also a proof-of-concept project for other bacterial pathogens of livestock.

ErhvervsPhD

Novo Nordisks patienter er dybt afhængige af at have adgang til innovative devices med høj pålidelighed. Øget brug af varians-baserede simuleringer i udviklingsprocessen ville kunne give design ingeniørerne en øget forståelse af hvordan devicet vil fungere i hele udfaldsområdet, dvs. inkl. varians fra produktion og brug. Udvikling af en proces og metoder til at lave sådanne simuleringer vil muliggøre hurtig udvikling af innovative og pålidelige devices, hvilket kommer patienterne til gode.

Parkinson’s sygdom er karakteriseret ved tab af dopamin neuroner i substantia nigra der medfører en ubalance imellem to sæt af projektions neuroner der danner den ’direkte vej’ og den ’indirekte vej’. I dette projekt vil vi forstå de neurokemiske ændringer der forekommer i hjerneregioner neden strøms for disse to sæt projektions neuroner efter aktivering eller deaktivering. Projektet vil øge den systemiske forståelse af patologien bag Parkinson’s sygdom til gavn for udvikling af lægemidler.

The scientific objectives of the MetaCat consortium are to deliver enzyme collections to industries, which encompass a high percentage of AFH enzymes (“all-round” and “frequent h it” enzymes). The enzyme classes we strive for include nitrilases, transaminases, ketoreductases, glycosyl hydrolases and lipases/esterases, which are of utmost importance for biotechnology. They can be implemented in the production of fine and platform chemicals, chiral building blocks and many other high-value compounds and their application usually results in a speed-up of synthesis routes and thus a significant reduction of the time to market. Special attention is paid to robust enzymes accepting large and bulky substrates

Peptider er en lovende klasse af molekyler til behandling af en lang række sygdomme. I nærværende projekt ønsker vi at udvikle en ny peptid-screenings platform som muliggør direkte selektion af enkelte funktionelt aktive peptider fra peptid-biblioteker som indeholder op til milliarder af individuelle peptider. Det forventes at etablering af en sådan screenings platform vil øge mulighederne for hurtigere at finde terapeutiske peptider med nye virkningsmekanismer og ønskede egenskaber.

Fase 1 er udvikling af CAPILLAQUA bæredygtig pottebakke med vandingssystem til transport af potteplanter. Systemet er "new to the world". Det medfører minimalspild, øget kvalitet af blomster og krydderurter fra jord til vindueskarm og løfter bæredygtigheden i branchen. 7 repræsentanter fra alle brancher i kæden fra gartneri til detail deltager i udviklingen og bliver fremtidige kunder. Der transporteres over 500.000.000 planter (min.10% spild) om året alene i DK i bakker med ca. 10 stk.

Peptider er en lovende klasse af molekyler til behandling af en lang række sygdomme. I nærværende projekt ønsker vi at udvikle en ny peptid-screenings platform som muliggør direkte selektion af enkelte funktionelt aktive peptider fra peptid-biblioteker som indeholder op til milliarder af individuelle peptider. Det forventes at etablering af en sådan screenings platform vil øge mulighederne for hurtigere at finde terapeutiske peptider med nye virkningsmekanismer og ønskede egenskaber.